D&O Disclosure Notices (Multiple)

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 5 February 2020
Date of last disclosure: 2 September 2019

Director or senior manager giving disclosure
Full name(s): Elizabeth Coutts
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s): Beneficial owner of shares
For that relevant interest -
Number held in class before acquisition or disposal: 915,649
Number held in class after acquisition or disposal: 1,165,649
Current registered holder(s):
Oceania Healthcare Holdings
Limited
Registered holder(s) once transfers are registered: Custodial Services Limited

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 30 January 2020
Nature of transaction: Acquisition of shares via
participation in a bookbuild
pursuant to an underwritten
selldown conducted by Oceania
Healthcare Holdings Limited
Name of any other party or parties to the transaction (if
known):
Oceania Healthcare Holdings
Limited
The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$300,000.00
Number of financial products to which the transaction
related:
250,000
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: N/A
Nature of relevant interest: N/A
For that relevant interest -
Number held in class: N/A
Current registered holder(s): N/A
For a derivative relevant interest -
Type of derivative: N/A

Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 5 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 5 February 2020
Date of last disclosure: 11 September 2019

Director or senior manager giving disclosure
Full name(s): Alan Isaac
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s): Beneficial owner of shares
For that relevant interest -
Number held in class before acquisition or disposal: 111,564
Number held in class after acquisition or disposal: 131,564
Current registered holder(s):
Oceania Healthcare Holdings
Limited
Registered holder(s) once transfers are registered: Alan Raymond Isaac, Andrew
John Dinsdale and Alasdair
Donald McBeth as trustees of
Isaac Family Trust

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A

The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 30 January 2020
Nature of transaction: Acquisition of shares via
participation in a bookbuild
pursuant to an underwritten
selldown conducted by Oceania
Healthcare Holdings Limited
Name of any other party or parties to the transaction (if
known):
Oceania Healthcare Holdings
Limited
The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$24,000.00
Number of financial products to which the transaction
related:
20,000
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares
Nature of relevant interest: Registered and beneficial owner
of shares
For that relevant interest -
Number held in class: (1) 111,912
(2) 5,000
Current registered holder(s): (1) Alan Isaac

(2) Mary Isaac
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 5 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 5 February 2020
Date of last disclosure: 2 September 2019

Director or senior manager giving disclosure
Full name(s): Kerry Prendergast
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Registered and beneficial owner
of shares
For that relevant interest -
Number held in class before acquisition or disposal: 203,477
Number held in class after acquisition or disposal: 303,477
Current registered holder(s): Oceania Healthcare Holdings
Limited
Registered holder(s) once transfers are registered: Kerry Prendergast

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 30 January 2020
Nature of transaction: Acquisition of shares via
participation in a bookbuild
pursuant to an underwritten
selldown conducted by Oceania
Healthcare Holdings Limited
Name of any other party or parties to the transaction (if
known):
Oceania Healthcare Holdings
Limited
The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$120,000.00
Number of financial products to which the transaction
related:
100,000
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: N/A
Nature of relevant interest: N/A
For that relevant interest -
Number held in class: N/A
Current registered holder(s): N/A
For a derivative relevant interest -
Type of derivative: N/A

Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 5 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 5 February 2020
Date of last disclosure: 2 September 2019

Director or senior manager giving disclosure
Full name(s): Sally Evans
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Registered and beneficial owner
of shares
For that relevant interest -
Number held in class before acquisition or disposal: 20,441
Number held in class after acquisition or disposal: 39,641
Current registered holder(s): Unknown
Registered holder(s) once transfers are registered: Sally Evans

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 30 January 2020
Nature of transaction: On market acquisition of shares
Name of any other party or parties to the transaction (if
known):
Unknown
The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$23,808.00
Number of financial products to which the transaction
related:
19,200
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: N/A
Nature of relevant interest: N/A
For that relevant interest -
Number held in class: N/A
Current registered holder(s): N/A
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A

A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 5 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 5 February 2020
Date of last disclosure: 2 September 2019

Director or senior manager giving disclosure
Full name(s): Gregory Tomlinson
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
Gregory Tomlinson has the power
to control the exercise of a right to
vote attached to the product and
the power to control the
acquisition and disposal of the
product.
For that relevant interest -
Number held in class before acquisition or disposal: 8,950,283
Number held in class after acquisition or disposal: 13,950,283
Current registered holder(s): Oceania Healthcare Holdings
Limited
Registered holder(s) once transfers are registered:
Tomlinson Group Investments
Limited

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A

Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 30 January 2020
Nature of transaction: Acquisition of shares via
participation in a bookbuild
pursuant to an underwritten
selldown conducted by Oceania
Healthcare Holdings Limited
Name of any other party or parties to the transaction (if
known):
Oceania Healthcare Holdings
Limited
The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$6,000,000.00
Number of financial products to which the transaction
related:
5,000,000
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares
Nature of relevant interest: Harrogate Trustee Limited or its
directors are accustomed to act in
accordance with Gregory
Tomlinson's wishes in relation to a

relevant interest held by
Harrogate Trustee Limited.
For that relevant interest -
Number held in class: 3,565,194
Current registered holder(s): Harrogate Trustee Limited
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 5 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 5 February 2020
Date of last disclosure: 27 May 2019

Director or senior manager giving disclosure
Full name(s): Patrick McCawe
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Director

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s):
As a director of Oceania
Healthcare Holdings Limited,
Patrick McCawe has the power to
control the exercise of rights
attaching to the shares held by
Oceania Healthcare Holdings
Limited, and the power to control
the acquisition or disposition of
such shares.
For that relevant interest -
Number held in class before acquisition or disposal: 251,202,979
Number held in class after acquisition or disposal: 0
Current registered holder(s): Oceania Healthcare Holdings
Limited
Registered holder(s) once transfers are registered: Various

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A

A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 30 January 2020
Nature of transaction: Sale of shares in Oceania
Healthcare Limited by Oceania
Healthcare Holdings Limited via
an underwritten block trade (and
bookbuild).
Name of any other party or parties to the transaction (if
known):
Unknown
The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$301,443,574.80
Number of financial products to which the transaction
related:
251,202,979
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares

Nature of relevant interest: Mr McCawe’s wife is the
registered and beneficial owner
of shares
For that relevant interest -
Number held in class: 250,000
Current registered holder(s): Joanne Lilian McCawe
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 5 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary

---

Ongoing Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 5 February 2020
Date of last disclosure: 26 September 2019

Director or senior manager giving disclosure
Full name(s): Jill Birch
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: General Manager Sales,
Marketing & Village Operations

Summary of acquisition or disposal of relevant interest (excluding derivatives)
Class of affected quoted financial products: Ordinary shares
Nature of the affected relevant interest(s): Registered and beneficial owner
of shares
For that relevant interest -
Number held in class before acquisition or disposal: 847,676
Number held in class after acquisition or disposal: 1,003,376
Current registered holder(s): Oceania Healthcare Holdings
Limited
Registered holder(s) once transfers are registered: Jill Birch

Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)
Type of affected derivative: N/A
Class of underlying financial products: N/A
Details of affected derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A

Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Details of transactions giving rise to acquisition or disposal
Total number of transactions to which notice relates: 1
Details of transactions requiring disclosure -
Date of transaction: 30 January 2020
Nature of transaction: Acquisition of shares via
participation in a bookbuild
pursuant to an underwritten
selldown conducted by Oceania
Healthcare Holdings Limited
Name of any other party or parties to the transaction (if
known):
Oceania Healthcare Holdings
Limited
The consideration, expressed in New Zealand dollars, paid
or received for the acquisition or disposal. If the
consideration was not in cash and cannot be readily
converted into a cash value, describe the consideration:
$186,840.00
Number of financial products to which the transaction
related:
155,700
If the issuer has a financial products trading policy that
prohibits directors or senior managers from trading during
any period without written clearance (a closed period)
include the following details -

Whether relevant interests were acquired or disposed of
during a closed period:
No
Whether prior written clearance was provided to allow the
acquisition or disposal to proceed during the closed period:
N/A
Date of the prior written clearance (if any): N/A

Summary of other relevant interests after acquisition or disposal:
Class of quoted financial products: Ordinary shares
Nature of relevant interest: (1) Beneficial owner of shares
pursuant to a long term incentive
plan, under which shares are
held by OCA Employees Trustee
Limited
(2) Beneficial interest in shares
issued under the terms of the
Oceania Healthcare Employee
Share Scheme, under which

shares are held by OCA
Employees Trustee Limited
For that relevant interest -
Number held in class: (1) 411,392
(2) 780
Current registered holder(s): OCA Employees Trustee Limited
For a derivative relevant interest -
Type of derivative: N/A
Details of derivative -
The notional value of the derivative (if any) or the notional
amount of underlying financial products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price’s specified terms (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A
For that derivative relevant interest:
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 5 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary

---

Initial Disclosure Notice
Disclosure of Directors and Senior Managers Relevant Interests
Sections 297(1) and 298(1), Financial Markets Conduct Act 2013

To NZX Limited; and ASX
Name of listed issuer: Oceania Healthcare Limited
Date this disclosure made: 5 February 2020
Date on which issuer listed or appointment made: 20 January 2020

Director or senior manager giving disclosure
Full name(s): Brent Pattison
Name of listed issuer: Oceania Healthcare Limited
Name of related body corporate (if applicable): N/A
Position held in listed issuer: Chief Financial Officer

Summary of relevant interest (excluding specified derivatives)
Class of quoted financial product: Ordinary shares
Number held in class: 200,000
Nature of relevant interest:
Registered and beneficial owner
of shares
Current registered holder: Brent Pattison

Summary of specified derivatives relevant interest (if applicable)
Type of derivative: N/A
Class of underlying financial products: N/A

Details of derivative
The notional value of the derivative (if any) or the notional
amount of underlying products (if any):
N/A
A statement as to whether the derivative is cash settled or
physically settled:
N/A
Maturity date of the derivative (if any): N/A
Expiry date of the derivative (if any): N/A
The price specified in the terms of the derivative (if any): N/A
Any other details needed to understand how the amount of
the consideration payable under the derivative or the value
of the derivative is affected by the value of the underlying
financial products:
N/A

For that derivative: -
Parties to the derivative: N/A
If the director or senior manager is not a party to the
derivative, the nature of the relevant interest in the
derivative:
N/A

Certification
I certify that, to the best of my knowledge and belief, the
information contained in this disclosure is correct and that I
am duly authorised to make this disclosure by all persons
for whom it is made.

Signature of director or officer:

Date of signature:
or
Signature of person authorised to sign on behalf of director
or officer:


Date of signature: 5 February 2020
Name and title of authorised person: Anna Thorburn
General Counsel & Company
Secretary